Varian touts proton therapy educational milestone
Varian Medical Systems is highlighting an educational milestone at the Maryland...Read more on AuntMinnie.comRelated Reading: Varian acquires decision-support firm India clears Varian's Halcyon radiation therapy system Varian acquires Mobius Medical Varian inks deal to acquire Sirtex for $1.3B Varian posts double-digit Q1 gain
Conditions: Clinical Stage I Esophageal Adenocarcinoma AJCC v8; Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Clinical Stage II Esophageal Squamous Cell Carcinom a AJCC v8; Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8; Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8; Clinica...
What can radiation oncology residents expect to find in the job market upon...Read more on AuntMinnie.comRelated Reading: Proton therapy works well for pediatric brain tumors ASTRO: RT, surgery up stage IV lung cancer survival ASTRO: SABR is effective for oligometastatic cancers ASTRO: Weekly breast radiation therapy is safe ASTRO: AI's rad therapy future is in predicting outcomes
In conclusion, the TOPAS-nBio extension to the TOPAS MC application offers access to accurate and detailed multiscale simulations, from a macroscopic description of the radiation field to microscopic description of biological outcome for selected cells. TOPAS-nBio offers detailed physics and chemistry simulations of radiobiological experiments on cells simulating the initially induced damage and links to models of DNA repair kinetics. PMID: 30609382 [PubMed - as supplied by publisher]
To shed light on the insurance approval process for proton radiation therapy, our study follows 903 patients who entered the process at a large volume proton therapy center, demonstrating significant treatment delays (median 21 days with appeal) associated with obtaining authorization. Furthermore, while insurance type reliably predicts for approval, several clinically-relevant factors may not be actively considered in coverage determinations, including trial enrollment, indication, and site, with overall approval rates decreasing over time.
This article is protected by copyright. All rights reserved.
Opinion statementNon-small cell lung cancer (NSCLC) accounts for 85% of new lung cancer cases and has 5-year survival rates ranging from 92% in early-stage disease to as low as 13% in locally advanced cases. Radiation therapy is a key component in the treatment repertoire for NSCLC, where it is currently used alone or in combinations with chemotherapy and surgery. Despite the broad use of modern photon radiation techniques, as many as 25% of patients experience isolated locoregional recurrences, and toxicity has been proven to be a limiting factor in many cases. Proton beam therapy (PBT) has emerged as a potential solution...
We developed and implemented a data-driven decision support system for identifying those oropharyngeal cancer patients likely to have the greatest benefit from proton therapy. We found that younger patients with p16-positive tumors who smoked ≤10 pack-years were estimated to have the most quality-adjusted life years (QALYs) spared with proton therapy, as compared to photon IMRT. Importantly, the estimated benefit of proton therapy depends strongly on the organ-at-risk doses achievable with photon IMRT.
In this study the RBE for the CHO-K1 cell line in a passively delivered clinical proton spread out Bragg peak (SOBP) is determined both in vitro and using a silicon-on-insulator (SOI) microdosimetry method paired with the modified microdosimetric kinetic model. The RBE along the central axis of a SOBP with 2 Gy delivered at the middle of the treatment field was found to vary between 1.11-1.98 and the RBE for 10% cell survival between 1.07-1.58 with a 250 kVp x-ray reference radiation and between 1.19-2.34 and 0.95-1.41, respectively, for a Co60 reference. Good agreement was found between RBE values calculated from the SOI-...
Postmastectomy radiation therapy (PMRT) has consistently shown benefits in decreasing the risk of locoregional recurrence and increasing long-term breast cancer-specific survival and overall survival rates for high-risk node positive breast cancer [1 –3]. A standard PMRT field includes chest wall and comprehensive coverage of the axillary and supraclavicular lymph nodes. The addition of internal mammary chain in the radiation field has been increasingly adopted and supported by data from randomized clinical trials [4–6].
With the increasing use of advanced radiation techniques such as intensity modulated radiation therapy, stereotactic radiation therapy, and proton therapy, radiation oncologists now have the tools to mitigate radiation-associated toxicities. This is of utmost importance in the treatment of a pediatric patient. To best utilize these advanced techniques to mitigate radiation-induced growth abnormalities, the radiation oncologist should be equipped with a nuanced understanding of the anatomy of centers of growth.